Reaction
Venous Occlusion reporting signals
As of the last recalculation, Venous Occlusion appears in 1,806 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is VALSARTAN AND HYDROCHLOROTHIAZIDE (PRR 29.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Valsartan And Hydrochlorothiazide | 34 | 29.4 | 29.5 |
| Captopril | 18 | 21.8 | 21.8 |
| Prasugrel Hydrochloride | 16 | 18.3 | 18.3 |
| Ticagrelor | 45 | 16.6 | 16.7 |
| Candesartan Cilexetil | 25 | 11.1 | 11.1 |
| Enalapril | 42 | 8.9 | 8.9 |
| Sitagliptin And Metformin Hydrochloride | 16 | 8.6 | 8.6 |
| Isosorbide Dinitrate | 14 | 8.3 | 8.3 |
| Paricalcitol | 10 | 8.2 | 8.2 |
| Brinzolamide | 6 | 8.0 | 8.0 |
| Nilotinib | 20 | 7.9 | 7.9 |
| Glimepiride | 25 | 7.5 | 7.5 |
| Amlodipine Besylate And Valsartan | 7 | 7.3 | 7.3 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 5 | 7.0 | 7.1 |
| Etonogestrel And Ethinyl Estradiol | 12 | 6.3 | 6.3 |
| Ranolazine | 5 | 5.5 | 5.5 |
| Alteplase | 6 | 4.6 | 4.6 |
| Ranibizumab | 10 | 4.4 | 4.4 |
| Vemurafenib | 4 | 3.8 | 3.8 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 10 | 3.7 | 3.7 |
| Patiromer | 3 | 2.5 | 2.5 |
| Cinacalcet Hydrochloride | 7 | 1.7 | 1.7 |
| Evolocumab | 18 | 1.3 | 1.3 |